From Wikipedia, the free encyclopedia
Jump to: navigation, search
CBS-0550 structure.png
Systematic (IUPAC) name
CAS Number 887289-02-3
PubChem CID 24763642
ChemSpider 23320245
Chemical data
Formula C20H23F4N3O
Molar mass 397.409 g/mol

CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB2 receptor agonist, with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects.[1] A number of related compounds have been developed with similar properties.[2]

See also[edit]


  1. ^ Ohta H, et al. Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. Bioorganic and Medicinal Chemistry. 2008 Feb 1;16(3):1111-24. PMID 18006322
  2. ^ Hiroshi Ohta; Tomoko Ishizaka; Makoto Tatsuzuki; Mitsukane Yoshinaga; Izumi Iida; Yasumitsu Tomishima; Yoshihisa Toda; Shuji Saito (November 2007). "N-Alkylidenearylcarboxamides as new potent and selective CB2 cannabinoid receptor agonists with good oral bioavailability". Bioorganic & Medicinal Chemistry Letters. 17 (22): 6299–6304. doi:10.1016/j.bmcl.2007.09.004. PMID 17884496.